Kazia Therapeutics Ltd Sponsored ADR Stock

$6.55

2.96%

Nasdaq, Jul 07, 10:06 pm CET

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kazia Therapeutics Ltd Sponsored ADR Stock price

$6.55

-179.95 96.49% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.20 2.96%

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$7.6m

Enterprise Value

$11.1m

Net debt

$3.5m

Cash

$1.1m

Shares outstanding

6.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

5.0 | -

EV/Sales

7.3 | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-46.4%

Return on Equity

267.3%

ROCE

650.9%

ROIC

-223.5%

Debt/Equity

-0.7

Financials (TTM | estimate)

Revenue

$1.5m | $0.0

EBITDA

- | $4.7m

EBIT

$-17.8m | $-24.0m

Net Income

$-17.4m | $-115.8m

Free Cash Flow

$-6.2m

Growth (TTM | estimate)

Revenue

15,000.0% | -100.0%

EBITDA

- | 128.4%

EBIT

-13.4% | -

Net Income

-30.9% | -559.6%

Free Cash Flow

36.8%

EPS

$-0.3

FCF per Share

$-0.9

Short interest

14.6%

Employees

Rev per Employee

$120.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	1.51 1.51	15,000% 15,000% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.81 8.81	58% 58% 583%
- Research and Development Expense	11 11	12% 12% 747%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-18 -18	13% 13% -1,177%
Net Profit	-17 -17	31% 31% -1,152%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral

PRNewsWire

●

27 days ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

SYDNEY , June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research that underscores the powerful potential of its lead...

Neutral

PRNewsWire

●

about one month ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer SYDNEY , June 5, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for diffic...

Neutral

PRNewsWire

●

about 2 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Awarded research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD) Launched clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer R...

More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	John Friend
Employees	13
Founded	1994
Website	www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now